e-Drug3D

1812

OSIMERTINIB

INN
OSIMERTINIB

cas 1421373-65-0

CLASS

ANTINEOPLASTIC
COVALENT KINASE INHIBITOR
TREATMENT OF METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
ALSO INHIBITED THE ACTIVITY OF HER2, HER3, HER4, ACK1 AND BLK

ROUTE (list)

ORAL

ATC code

L01EB04

PK parameters

Tmax 6 HOUR
VD 986 LITER
Cl 14.2 LITER / HOUR
t1/2 48 HOUR

Target

TARGET EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

PDB
4ZAU (AZD9291 COMPLEX WITH WILD TYPE EGFR)

Ligand code = YY3 (link to the list of PDB complexes)

Download experimental 3D coordinates of YY3 with added hydrogens

DrugCentral

Epidermal growth factor receptor UNIPROT P00533 EGFR

Download SDF file

2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-

Formula:
C28H33N7O2

Calculated chemical properties:

MW 499.61
NB_atoms 37
XLogP 4.51
PSA 80.639
NB_HD 2
NB_HA 9
fsp3 0.25
Lipinski(0=no;1=yes) 1

FDA
NDA 208065 (pdf not found) INN (OSIMERTINIB MESYLATE) TAGRISSO (ASTRAZENECA) APPROVAL= AP YEAR= 2015
NDA 214263 (pdf not found) INN (OSIMERTINIB MESYLATE) OSIMERTINIB MESYLATE (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2021